Navigation Links
Landmark trial to evaluate cardioprotective properties of insulin
Date:11/9/2007

BUFFALO, N.Y. -- The ability of insulin to limit heart-tissue damage during a heart attack will be tested in a landmark clinical trial led by Paresh Dandona, M.D., Ph.D., University at Buffalo Distinguished Professor in the departments of Medicine and Pharmacology and Toxicology in the UB School of Medicine and Biomedical Sciences.

Approximately 600 patients at 90 centers in the U.S. and Latin America will be recruited to participate in the two-year INTENSIVE (Intensive Insulin Therapy and Size of Infarct as a Validated Endpoint by Cardiac MRI) trial. Patients in the trial, which is funded by sanofi-aventis, will be treated with two forms of insulin -- insulin glargine and insulin glulisine.

Kaleida Healths Diabetes-Endocrine Center of Western New York, which Dandona directs, will be one of the vanguard centers. The centers research facility, located in UBs New York State Center of Excellence in Bioinformatics and Life Sciences, will serve as the core laboratory.

Richard W. Nesto, M.D., associate professor at Harvard Medical School and chair of cardiovascular medicine at Lahey Clinic Medical Center in Burlington, Mass., will be co-principal investigator, directing the trials cardiovascular aspects.

The trial is based on a pilot study conducted by the diabetes center, which documented that insulin, used to treat and control type 1 and type 2 diabetes, was also cardioprotective.

This pilot study, published in the journal Circulation in 2004, was conducted in 32 patients receiving low-dose insulin. C-reactive protein (CRP) and serum amyloid A (SAA), two critical markers of inflammation, were reduced by 40 percent and 50 percent, respectively, during the 48 hours following a heart attack. Concentrations of three additional inflammatory factors also were significantly lower in those who received insulin, compared to those who did not.

The markers of myocardial damage that we measured were reduced significantly, said Dandona. We are excited to learn more about the potential cardioprotective benefits we may discover with insulin. We think insulin will improve blood flow during a heart attack and help limit damage to heart tissue.

Previous studies evaluating the potential benefits of insulin were confounded by glucose levels that went up simultaneously, because patients were given too much glucose.

The INTENSIVE trial will involve infusing relatively higher concentrations of insulin compared to glucose. The treatment will be tailored to those patients with diabetes who would benefit most -- patients with glucose above 140 mg/dL on admission and who have an anterior wall heart attack -- the largest type of heart attack.

This is the first large-scale trial that will be conducted using this individually tailored treatment strategy in patients who are undergoing a coronary procedure (PCI) for their heart attack, said Nesto.

During the two-to-three months post-heart attack period, patients will undergo an MRI, which can detect subtle change in cardiac structure and function. The MRI technology being used in the INTENSIVE trial is at the forefront of cardiac imaging, Nesto said.


'/>"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-5000 x1417
University at Buffalo
Source:Eurekalert

Related medicine news :

1. Document Security Systems (Amex: DMC) Invites You to a Landmark Event
2. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
3. Pathway to cell death redefined in landmark study
4. Pathway to cell death redefined in landmark study
5. UCLA to lead local study center in landmark government study of child health
6. Landmark Report: Excess Body Fat Causes Cancer
7. In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
8. New Heart Pump Shows Promise in Trial
9. Trial to Test Gene Therapy for Angina in Women
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... An increase in wetter weather in the ... and along with that; a humdinger of an allergy season. A relief from drought ... increase in misery-causing grass and weed pollen. , “Our patients have been reporting ...
(Date:6/24/2017)... ... 24, 2017 , ... The Pennsylvania Athletic Trainers’ Society’s (PATS) ... Erie Convention Center on June 8-10. The weekend consisted of many educational ... and scholarship presentations, and professional networking. , On Friday June 9th, PATS ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better ... ultimately do significant harm to people with all chronic conditions, including mental illnesses, ... leaves in place the Affordable Care Act (ACA) requirement that insurers cover pre-existing ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. Rubinstein ... recently begun offering three new minimally invasive procedures to patients who want a ... downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet rich ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... essential, and two new videos highlight the importance of correctly using a meat ... Ph.D., who has done extensive research on consumer food safety habits. Dr. Bruhn ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... 22, 2017  Lilac Corp, the company that ... launch of a new website . The ... a clinical study that showed surprising clearance of ... in individuals suffering from HPV warts, precancerous, or ... are no other treatments that clear the virus. ...
(Date:5/18/2017)... 2017  Two Bayer U.S. Pharmaceutical leaders received top ... recent 28 th Woman of the Year ... HBA,s longstanding mission of furthering the advancement and impact ... Cindy Powell-Steffen , senior director of brand activation ... Libby Howe , a regional business manager for ...
(Date:5/15/2017)... ATLANTA , May 15, 2017  Amy Baxter ... the industry leader in noninvasive pain relief, was awarded ... MM&M magazine. Baxter was recognized at the MM&M ... New York City on May 10, ... helping the biopharma industry go "beyond the pill."  ...
Breaking Medicine Technology: